Oncology Biosimilars Market

Oncology Biosimilars Market Analysis by Drug Class (G-CSF, Monoclonal Antibody, Hematopoietic Agents), by Disease Indication (Breast Cancer, Colorectal Cancer, Neutropenia, Leukemia) by Distribution Channel, by Region - Global Insights 2022-2032

Analysis of Oncology Biosimilars market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Table of Content

1. Preface

    1.1. Market Definition and Scope

    1.2. Research Highlights

2. Assumptions and Research Methodology

    2.1. Assumptions & Acronyms Used

    2.2. Research Methodology

3. Executive Summary: Global Oncology Biosimilar Market

    3.1. Executive Summary

    3.2. Market Opportunity Map

    3.3. Market Overview

    3.4. Key Industry Developments

    3.5. Global Oncology Biosimilar Market Size (US$ Mn) Forecast, 2022-2032

    3.6. Global Oncology Biosimilar Market Outlook

4. Market Dynamics

    4.1. Drivers

    4.2. Restraints

    4.3. Opportunity

    4.4. Key Trends

5. Porter’s Five Force Analysis

6. Oncology Biosimilars: Key Molecules

7. Biosimilars Market Snapshot

8. Cancer Statistics

9. Global Oncology Biosimilars Market Analysis and Forecasts, By Drug Class

    9.1. Introduction & Definition

    9.2. Key Findings

    9.3. Global Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032

    9.4. Market Attractiveness by Drug Class

    9.5. Global Oncology Biosimilars Market Forecast, by Drug Class, 2022-2032

        9.5.1. G-CSF

        9.5.2. Monoclonal Antibody

        9.5.3. Hematopoietic Agents

    9.6. Global Oncology Biosimilars Market Analysis, by Drug Class, 2022-2032

    9.7. Key Trends

10. Global Oncology Biosimilars Market Analysis and Forecasts, By Disease Indication

    10.1. Introduction & Definition

    10.2. Key Findings

    10.3. Global Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032

    10.4. Market Attractiveness by Disease Indication

    10.5. Global Oncology Biosimilars Market Forecast, by Disease Indication, 2022-2032

        10.5.1. Breast Cancer

        10.5.2. Non-Small Cell lung Cancer

        10.5.3. Blood Cancer

            10.5.3.1. Leukemia

                10.5.3.1.1. Myeloid Leukemia

                10.5.3.1.2. Chronic Lymphocytic Leukemia

                10.5.3.1.3. Others

            10.5.3.2. Non-Hodgkin Lymphoma

        10.5.4. Colorectal Cancer

        10.5.5. Neutropenia

        10.5.6. Others

    10.6. Global Oncology Biosimilars Market Analysis, by Disease Indication, 2022-2032

    10.7. Key Trends

11. Global Oncology Biosimilars Market Analysis and Forecasts, By Distribution Channel

    11.1. Introduction & Definition

    11.2. Key Findings

    11.3. Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032

    11.4. Market Attractiveness By Distribution Channel

    11.5. Global Oncology Biosimilars Market Forecast, by Distribution Channel, 2022-2032

        11.5.1. Hospital Pharmacy

        11.5.2. Online Pharmacy

        11.5.3. Retail Pharmacy

    11.6. Global Oncology Biosimilars Market Analysis, by Distribution Channel, 2022-2032

    11.7. Key Trends

12. Global Oncology Biosimilars Market Analysis and Forecasts, By Region

    12.1. Global Market Scenario

    12.2. Global Oncology Biosimilars Market Value Share, by Region, 2022 and 2032

    12.3. Global Oncology Biosimilars Market Attractiveness, by Region, 2022-2032

    12.4. Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2022-2032

        12.4.1. North America

        12.4.2. Europe

        12.4.3. Asia Pacific

        12.4.4. Rest of the World

13. North America Oncology Biosimilars Market Analysis and Forecast

    13.1. North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032

    13.2. North America Oncology Biosimilars Market Value Share, by Country, 2022 and 2032

    13.3. North America Oncology Biosimilars Market Attractiveness, by Country, 2022-2032

    13.4. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032

        13.4.1. U.S.

        13.4.2. Canada

    13.5. North America Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032

    13.6. North America Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032

    13.7. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

        13.7.1. G-CSF

        13.7.2. Monoclonal Antibody

        13.7.3. Hematopoietic Agents

    13.8. North America Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032

    13.9. North America Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032

    13.10. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032

        13.10.1. Breast Cancer

        13.10.2. Non-Small Cell lung Cancer

        13.10.3. Blood Cancer

            13.10.3.1. Leukemia

                13.10.3.1.1. Myeloid Leukemia

                13.10.3.1.2. Chronic Lymphocytic Leukemia

                13.10.3.1.3. Others

            13.10.3.2. Non-Hodgkin Lymphoma

        13.10.4. Colorectal Cancer

        13.10.5. Neutropenia

        13.10.6. Others

    13.11. North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032

    13.12. North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032

    13.13. North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032

        13.13.1. Hospital Pharmacy

        13.13.2. Online Pharmacy

        13.13.3. Retail Pharmacy

    13.14. Key Trends

14. Europe Oncology Biosimilars Market Analysis and Forecast

    14.1. Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032

    14.2. Europe Oncology Biosimilars Market Value Share, by Country, 2022 and 2032

    14.3. Europe Oncology Biosimilars Market Attractiveness, by Country, 2022-2032

    14.4. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032

        14.4.1. U.K.

        14.4.2. Germany

        14.4.3. France

        14.4.4. Italy

        14.4.5. Russia

        14.4.6. Spain

        14.4.7. Rest of Europe

    14.5. Europe Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032

    14.6. Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032

    14.7. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

        14.7.1. G-CSF

        14.7.2. Monoclonal Antibody

        14.7.3. Hematopoietic Agents

    14.8. Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032

    14.9. Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032

    14.10. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032

        14.10.1. Breast Cancer

        14.10.2. Non-Small Cell lung Cancer

        14.10.3. Blood Cancer

            14.10.3.1. Leukemia

                14.10.3.1.1. Myeloid Leukemia

                14.10.3.1.2. Chronic Lymphocytic Leukemia

                14.10.3.1.3. Others

            14.10.3.2. Non-Hodgkin Lymphoma

        14.10.4. Colorectal Cancer

        14.10.5. Neutropenia

        14.10.6. Others

    14.11. Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032

    14.12. Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032

    14.13. Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032

        14.13.1. Hospital Pharmacy

        14.13.2. Online Pharmacy

        14.13.3. Retail Pharmacy

    14.14. Key Trends

15. Asia Pacific Oncology Biosimilars Market Analysis and Forecast

    15.1. Asia Pacific Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032

    15.2. Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2022 and 2032

    15.3. Asia Pacific Oncology Biosimilars Market Attractiveness, by Country, 2022-2032

    15.4. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032

        15.4.1. China

        15.4.2. India

        15.4.3. Japan

        15.4.4. Australia & New Zealand

        15.4.5. Rest of Asia Pacific

    15.5. Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032

    15.6. Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032

    15.7. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

        15.7.1. G-CSF

        15.7.2. Monoclonal Antibody

        15.7.3. Hematopoietic Agents

    15.8. Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032

    15.9. Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032

    15.10. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032

        15.10.1. Breast Cancer

        15.10.2. Non-Small Cell lung Cancer

        15.10.3. Blood Cancer

            15.10.3.1. Leukemia

                15.10.3.1.1. Myeloid Leukemia

                15.10.3.1.2. Chronic Lymphocytic Leukemia

                15.10.3.1.3. Others

            15.10.3.2. Non-Hodgkin Lymphoma

        15.10.4. Colorectal Cancer

        15.10.5. Neutropenia

        15.10.6. Others

    15.11. Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032

    15.12. Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032

    15.13. Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032

        15.13.1. Hospital Pharmacy

        15.13.2. Online Pharmacy

        15.13.3. Retail Pharmacy

    15.14. Key Trends

16. Rest of the World Oncology Biosimilars Market Analysis and Forecast

    16.1. Rest of the World Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032

    16.2. Rest of the World Oncology Biosimilars Market Value Share, by Country, 2022 and 2032

    16.3. Rest of the World Oncology Biosimilars Market Attractiveness, by Country, 2022-2032

    16.4. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032

        16.4.1. Mexico

        16.4.2. Brazil

        16.4.3. Rest of the World

    16.5. Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032

    16.6. Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032

    16.7. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

        16.7.1. G-CSF

        16.7.2. Monoclonal Antibody

        16.7.3. Hematopoietic Agents

    16.8. Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032

    16.9. Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032

    16.10. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032

        16.10.1. Breast Cancer

        16.10.2. Non-Small Cell lung Cancer

        16.10.3. Blood Cancer

            16.10.3.1. Leukemia

                16.10.3.1.1. Myeloid Leukemia

                16.10.3.1.2. Chronic Lymphocytic Leukemia

                16.10.3.1.3. Others

            16.10.3.2. Non-Hodgkin Lymphoma

        16.10.4. Colorectal Cancer

        16.10.5. Neutropenia

        16.10.6. Others

    16.11. Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032

    16.12. Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032

    16.13. Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032

        16.13.1. Hospital Pharmacy

        16.13.2. Online Pharmacy

        16.13.3. Retail Pharmacy

    16.14. Key Trends

17. Competition Landscape

    17.1. Market Player – Competition Matrix (By Tier and Size of companies)

    17.2. Market Share Analysis By Company (2021)

18. Company Profiles

    18.1. Sandoz International GmbH

        18.1.1. Company Details

        18.1.2. Business Overview

        18.1.3. Financial Overview

        18.1.4. Strategic Overview

        18.1.5. SWOT Analysis

    18.2. Pfizer, Inc.

        18.2.1. Company Details

        18.2.2. Business Overview

        18.2.3. Financial Overview

        18.2.4. Strategic Overview

        18.2.5. SWOT Analysis

    18.3. Celltrion Inc.

        18.3.1. Company Details

        18.3.2. Business Overview

        18.3.3. Financial Overview

        18.3.4. Strategic Overview

        18.3.5. SWOT Analysis

    18.4. Dr. Reddy’s Laboratories Ltd.

        18.4.1. Company Details

        18.4.2. Business Overview

        18.4.3. Financial Overview

        18.4.4. Strategic Overview

        18.4.5. SWOT Analysis

    18.5. Biocon

        18.5.1. Company Details

        18.5.2. Business Overview

        18.5.3. Financial Overview

        18.5.4. Strategic Overview

        18.5.5. SWOT Analysis

    18.6. Teva Pharmaceutical Industries Ltd.

        18.6.1. Company Details

        18.6.2. Business Overview

        18.6.3. Financial Overview

        18.6.4. Strategic Overview

        18.6.5. SWOT Analysis

    18.7. STADA Arzneimittel AG

        18.7.1. Company Details

        18.7.2. Business Overview

        18.7.3. Financial Overview

        18.7.4. Strategic Overview

        18.7.5. SWOT Analysis

    18.8. Apotex Inc. (Apobiologix)

        18.8.1. Company Details

        18.8.2. Business Overview

        18.8.3. Financial Overview

        18.8.4. Strategic Overview

        18.8.5. SWOT Analysis

    18.9. Intas Pharmaceuticals Ltd.

        18.9.1. Company Details

        18.9.2. Business Overview

        18.9.3. Financial Overview

        18.9.4. Strategic Overview

        18.9.5. SWOT Analysis

    18.10. BIOCAD

        18.10.1. Company Details

        18.10.2. Business Overview

        18.10.3. Financial Overview

        18.10.4. Strategic Overview

        18.10.5. SWOT Analysis

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Global Biosimilars Market Snapshot

Table 02: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

Table 03: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032

Table 04: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, Blood Cancer, 2022-2032

Table 05: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032

Table 06: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032

Table 07: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, by Region, 2022-2032

Table 08: Approved Oncology Biosimilars by USFDA in new biosimilars pathway established under BPCIA Act

Table 09: North America Oncology Biosimilars: Pipeline Overview, 2017-2020

Table 10: North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032

Table 11: North America Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032

Table 12: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032

Table 13: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

Table 14: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032

Table 15: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032

Table 16: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032

Table 17: Europe Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032

Table 18: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032

Table 19: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Drug Class, 2022-2032

Table 20: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032

Table 21: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032

Table 22: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032

Table 23: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032

Table 24: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Country, 2022-2032

Table 25: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, Drug Class, 2022-2032

Table 26: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Disease Indication, 2022-2032

Table 27: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Blood Cancer, 2022-2032

Table 28: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Leukemia, 2022-2032

Table 29: Rest of the World Oncology Biosimilars Market Size (US$ Mn) Forecast, by Distribution Channel, 2022-2032

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Fig. 01: Global Oncology Biosimilars Market Size (US$ Mn) Forecast, 2022-2032

Fig. 02: Global Oncology Biosimilars Market Value Share, by Drug Class (2021)

Fig. 03: Global Oncology Biosimilars Market Value Share, by Disease Indication (2021)

Fig. 04: Global Oncology Biosimilars Market Value Share, by Distribution Channel (2021)

Fig. 05: Global Oncology Biosimilars Market Value Share, by Region (2021)

Fig. 06: U.S. Prevalence Share (%), By Cancer Type, 2015

Fig. 07: Global Estimation of Cancer, By New Cases & Deaths, 2021

Fig. 08: Global Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032

Fig. 09: Global Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032

Fig. 10: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Monoclonal Antibody, 2022-2032

Fig. 11: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hematopoietic Agents, 2022-2032

Fig. 12: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by G-CSF, 2022-2032

Fig. 13: Global Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032

Fig. 14: Global Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032

Fig. 15: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Breast Cancer, 2022-2032

Fig. 16: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Non-small Cell Lung Cancer, 2022-2032

Fig. 17: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Blood Cancer, 2022-2032

Fig. 18: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Colorectal Cancer, 2022-2032

Fig. 19: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Neutropenia, 2022-2032

Fig. 20: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Others, 2022-2032

Fig. 21: Global Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032

Fig. 22: Global Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032

Fig. 23: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacy, 2022-2032

Fig. 24: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Retail Pharmacy, 2022-2032

Fig. 25: Global Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacy, 2022-2032

Fig. 26: Global Oncology Biosimilars Market Value Share, by Region, 2022 and 2032

Fig. 27: Global Oncology Biosimilars Market Attractiveness, by Region, 2022-2032

Fig. 28: North America Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032

Fig. 29: North America Oncology Biosimilars Market Value Share, by Country, 2022 and 2032

Fig. 30: North America Oncology Biosimilars Market Attractiveness, by Country, 2022-2032

Fig. 31: North America Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032

Fig. 32: North America Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032

Fig. 33: Europe Oncology Biosimilars Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032

Fig. 34: Europe Oncology Biosimilars Market Value Share, by Country, 2022 and 2032

Fig. 35: Europe Oncology Biosimilars Market Attractiveness, by Country, 2022-2032

Fig. 36: Europe Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032

Fig. 37: Europe Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032

Fig. 38: Europe Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032

Fig. 39: Europe Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032

Fig. 40: Europe Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032

Fig. 41: Europe Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032

Fig. 42: Asia Pacific Oncology Biosimilars Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2022-2032

Fig. 43: Asia Pacific Oncology Biosimilars Market Value Share, by Country, 2022 and 2032

Fig. 44: Asia Pacific Oncology Biosimilars, Market Attractiveness, by Country, 2022-2032

Fig. 45: Asia Pacific Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032

Fig. 46: Asia Pacific Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032

Fig. 47: Asia Pacific Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032

Fig. 48: Asia Pacific Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032

Fig. 49: Asia Pacific Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032

Fig. 50: Asia Pacific Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032

Fig. 51: Rest of the World Oncology Biosimilars, Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2022-2032

Fig. 52: Rest of the World Oncology Biosimilars Market Value Share, by Country, 2022 and 2032

Fig. 53: Rest of the World Oncology Biosimilars, Market Attractiveness, by Country, 2022-2032

Fig. 54: Rest of the World Oncology Biosimilars Market Value Share, by Drug Class, 2022 and 2032

Fig. 55: Rest of the World Oncology Biosimilars Market Attractiveness, by Drug Class, 2022-2032

Fig. 56: Rest of the World Oncology Biosimilars Market Value Share, by Disease Indication, 2022 and 2032

Fig. 57: Rest of the World Oncology Biosimilars Market Attractiveness, by Disease Indication, 2022-2032

Fig. 58: Rest of the World Oncology Biosimilars Market Value Share, by Distribution Channel, 2022 and 2032

Fig. 59: Rest of the World Oncology Biosimilars Market Attractiveness, by Distribution Channel, 2022-2032

Fig. 60: Global Oncology Biosimilars Market Share, by Company, 2021

Fig. 61: Breakdown of Net Sales of Sandoz International GmbH (A Novartis Division), by Franchise, 2021 (%)

Fig. 62: Revenue (US$ Bn) & Y-o-Y Growth (%) of Sandoz International GmbH (A Novartis Division), 2015-2021

Fig. 63: Breakdown of Net Sales of Pfizer, Inc., by Region, 2021 (%)

Fig. 64: Revenue (US$ Bn) & Y-o-Y Growth (%) of Pfizer, Inc., 2015-2021

Fig. 65: Breakdown of Net Sales of Celltrion Inc., by Business Segments, 2021

Fig. 66: Revenue (US$ Mn) & Y-o-Y Growth (%) of Celltrion Inc., 2015-2021

Fig. 67: Breakdown of Net Sales of Dr. Reddy’s Laboratories Ltd., by Business Segments, 2021 (%)

Fig. 68: Revenue (US$ Bn) & Y-o-Y Growth (%) of Dr. Reddy’s Laboratories Ltd., 2015-2021

Fig. 69: Breakdown of Net Sales of Biocon, by Business Segments, 2021 (%)

Fig. 70: Revenue (US$ Mn) & Y-o-Y Growth (%) of Biocon, 2015-2021

Fig. 71: Breakdown of Net Sales of Teva Pharmaceutical Industries Ltd., by Business Segments, 2021 (%)

Fig. 72: Revenue (US$ Bn) & Y-o-Y Growth (%) of Teva Pharmaceutical Industries Ltd., 2015-2021

Fig. 73: Breakdown of Net Sales of STADA Arzneimittel AG, by Business Segments, 2021 (%)

Fig. 74: Revenue (US$ Bn) & Y-o-Y Growth (%) of STADA Arzneimittel AG, 2015-2021

Fig. 75: Revenue (US$ Mn) & Y-o-Y Growth (%) of Intas Pharmaceuticals Ltd., 2015-2021

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Oncology Biosimilars Market

Schedule a Call